AARD Long Call Strategy
AARD (Aardvark Therapeutics, Inc. Common Stock), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Aardvark Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, concentrating on developing small-molecule treatments. These therapies are designed to stimulate the body's natural regulatory systems (innate homeostatic pathways) to combat metabolic disorders. The company's primary experimental drug, ARD-101, is an orally administered, gut-specific small molecule. It functions as an agonist, targeting particular bitter taste receptors found within the gut lumen. ARD-101 is currently undergoing a Phase III clinical trial for managing excessive hunger (hyperphagia) associated with Prader-Willi Syndrome. Additionally, it is in a Phase II trial for addressing hyperphagia linked to acquired hypothalamic obesity, often a result of craniopharyngioma treatments like surgery or radiation therapy.
AARD (Aardvark Therapeutics, Inc. Common Stock) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $143.8M, a beta of 3.81 versus the broader market, a 52-week range of 3.35-17.94, average daily share volume of 238K, a public-listing history dating back to 2025, approximately 40 full-time employees. These structural characteristics shape how AARD stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 3.81 indicates AARD has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.
What is a long call on AARD?
A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration.
AARD snapshot
As of August 14, 2026, spot at $6.53, ATM IV 191.70%, IV rank 38.20%, expected move 54.96%. The long call on AARD below is built from the end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 35-day expiry.
Why this long call structure on AARD specifically: AARD IV at 191.70% is mid-range versus its 1-year history, so strategy selection should anchor more to the directional thesis than to the IV regime, with a market-implied 1-standard-deviation move of approximately 54.96% (roughly $3.59 on the underlying). The 35-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated AARD expiries trade a higher absolute premium for lower per-day decay. Position sizing on AARD should anchor to the underlying notional of $6.53 per share and to the trader's directional view on AARD stock.
AARD long call setup
The AARD long call below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With AARD at $6.53 on that close, the first option leg uses a $6.53 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed AARD chain at a 35-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 AARD shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $6.53 | N/A |
AARD long call risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium.
AARD long call payoff curve
Modeled P&L at expiration across a range of underlying prices for the long call on AARD. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use long call on AARD
Long calls on AARD express a bullish thesis with defined risk; traders use them ahead of AARD catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
AARD thesis for this long call
The market-implied 1-standard-deviation range for AARD extends from approximately $2.94 on the downside to $10.12 on the upside. A AARD long call expresses a directional view that the underlying closes above the strike plus premium at expiration, ideally with implied volatility holding or expanding to preserve extrinsic value through the hold period. Current AARD IV rank near 38.20% is mid-range against its 1-year distribution, so the IV signal is neutral; the long call thesis on AARD should anchor more to the directional view and the expected-move geometry. As a Healthcare name, AARD options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to AARD-specific events.
AARD long call positions are structurally bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. AARD positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move AARD alongside the broader basket even when AARD-specific fundamentals are unchanged. Long-premium structures like a long call on AARD are particularly exposed to IV-crush risk through scheduled events (earnings, FDA decisions, central-bank meetings) where IV typically contracts post-event regardless of the directional outcome. Always rebuild the position from current AARD chain quotes before placing a trade.
Frequently asked questions
- What is a long call on AARD?
- A long call on AARD is the long call strategy applied to AARD (stock). The strategy is structurally bullish: A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration. With AARD stock at $6.53 on the most recent close, the strikes shown on this page are snapped to the nearest listed AARD chain strike and the premiums come straight from that session's bid/ask midpoint.
- How are AARD long call max profit and max loss calculated?
- Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium. For the AARD long call priced from the end-of-day chain at a 30-day expiry (ATM IV 191.70%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a AARD long call?
- The breakeven for the AARD long call priced on this page is no defined breakeven on the modeled curve at expiration, derived from the end-of-day chain's premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The AARD market-implied 1-standard-deviation expected move in the same options snapshot is approximately 54.96%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a long call on AARD?
- Long calls on AARD express a bullish thesis with defined risk; traders use them ahead of AARD catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
- How does current AARD implied volatility affect this long call?
- AARD ATM IV is at 191.70% with IV rank near 38.20%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.